Selexipag Suppliers & Bulk Manufacturers

Available Forms: Tablets / Injection

Available Strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg

Reference Brands: Uptravi (USA/EU)

Category: Heart Disorder

Product Description:

Selexipag is a selective prostacyclin (IP) receptor agonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). It is used to delay disease progression and reduce the risk of hospitalization associated with PAH. Developed by Actelion, Selexipag represents an advanced, non-prostanoid therapeutic option that targets the prostacyclin pathway, a key mechanism involved in pulmonary vascular remodeling and increased pulmonary arterial pressure.

After oral or intravenous administration, Selexipag is rapidly metabolized into its active metabolite, ACT-333679 (also known as MRE-269), which exhibits a high affinity for the prostacyclin receptor. Activation of this receptor leads to vasodilation of the pulmonary arteries, inhibition of smooth muscle cell proliferation, and improved pulmonary blood flow. Unlike traditional prostacyclin analogues, Selexipag offers targeted receptor activity with a more convenient dosing profile.

Selexipag can be administered as oral tablets for chronic therapy or intravenously for patients who are temporarily unable to take oral medication. It is commonly used as monotherapy or in combination with other PAH treatments, including endothelin receptor antagonists and phosphodiesterase-5 inhibitors, making it a valuable option in comprehensive PAH management strategies.